Abstract
In long-term dialysis patients, Al accumulation poses a problem, and deferoxamine (DFO) administration is proposed to be an effective therapy. However, DFO has numerous side effects. Therefore, an optimal dose should be administered in hemodialysis patients. In the present investigation, we administered 0.5g of DFO per week to one group and 0.5g twice a week to the other group, attempting to remove the Al during HD using BK-1, OH (PMMA membrane). In the first group the DFO level one week after administration was 186±37.8μg/L, and 151.7± 73.1μg/L at 8 weeks, reflecting minimum accumulation. In the second group, the level rose to 400-500μg/L after 8 weeks of treatment, revealing a definite accumulation. The Al concentration tended to decline with DFO treatment in either group, but no significant difference was noted between two groups. From the foregoing, given the side effects as well as the efficacy, a weekly DFO dose of 0.5g was considered to be suitable for long-term treatment.
